Aeolus Pharmaceuticl (AOLS) 0.3596 $AOLS Aeolus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeolus Pharmaceuticl (AOLS) 0.3596 $AOLS

Aeolus Announces Second Quarter Fiscal Year 2015 Financial Results
Marketwired - Fri May 15, 3:53PM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three and six months ended March 31, 2015.

Aeolus Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
Marketwired - Mon May 04, 6:30AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)

Aeolus Pharmaceuticals, Inc. - Product Pipeline Review - 2015
M2 - Fri Apr 17, 2:46AM CDT
This report provides comprehensive information on the current therapeutic developmental pipeline of Aeolus Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Aeolus Files Patent Application and Completes Licensure of New Series of Compounds to Treat Infectious and Inflammatory Disease
Marketwired - Wed Apr 15, 7:01AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has filed a provisional patent application with the United States Patent Office for a new series of compounds demonstrating anti-microbial and anti-inflammatory action. The compounds were developed by Brian J. Day, PhD at National Jewish Health in Denver, Colorado as a result of an Aeolus-sponsored research grant. Aeolus also announced that it has obtained a worldwide, exclusive license to develop the compounds from National Jewish Health.

Aeolus Receives Notice of Allowance From Israeli Patent Office for Use of AEOL 10150 and Other Aeolus Compounds to Treat Injury From Exposure to Alkylating Agents Such as Sulfur Mustard Gas
Marketwired - Tue Mar 31, 7:03AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received a Notice of Allowance from the Israeli Patent Office for application number 209435, "Methods for Treating Injury Associated with Exposure to an Alkylating Species." The patent covers Aeolus' lead compound, AEOL 10150 as well as other metalloporphyrins under development by the Company. Alkylating agents include chemical gas agents such as sulfur mustard gas.

Aeolus wins US FDA's orphan drug designation for AEOL 10150 for treating idiopathic pulmonary fibrosis
M2 - Wed Mar 18, 6:55AM CDT
Biotechnology company Aeolus Pharmaceuticals (OtherOTC:AOLS) reported on Tuesday the receipt of orphan drug designation for AEOL 10150 for treatment of idiopathic pulmonary fibrosis from from the Office of Orphan Products Development at the US Food & Drug Administration (FDA).

Aeolus Pharma antioxidant an Orphan Drug for lung disease
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 12:38PM CDT


Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
Marketwired - Tue Mar 17, 10:46AM CDT
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today that it has received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 "for treatment of idiopathic pulmonary fibrosis." Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.

Aeolus' Q1 fiscal 2015 net loss widens to USD698,000
M2 - Mon Feb 16, 3:00AM CST
Biotechnology company Aeolus Pharmaceuticals (Other OTC:AOLS) stated on Friday that it recorded a net loss of USD698,000 (USD0.01 per share) for the three months ended 31 December 2014.

Aeolus Announces First Quarter Fiscal Year 2015 Financial Results
Marketwired - Fri Feb 13, 4:42PM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced today financial results for the three months ended December 31, 2014.

Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.24 (-3.11), PSTI: 2.68 (-0.01), ASPX: 100.96 (unch), LPTN: 1.83 (+0.04), IBIO: 0.89 (+0.04), FGEN: 20.38 (-1.01), AQXP: 7.34 (-0.17), GALT: 2.76 (+0.07), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), GILD: 109.30 (+0.56), CGEN: 6.45 (-0.03), FPRX: 21.11 (-0.06), CELGZ: 2.60 (-0.10)

Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150
Marketwired - Thu Jan 08, 7:31AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that it has filed a formal mitigation response to the Division of Medical Imaging Products ("DMIP" of the U.S. Food and Drug Administration ("FDA" after consultation with its development partner, the Biomedical Advanced Research and Development Authority ("BARDA" . The response addresses the questions cited by the DMIP when it placed a clinical hold on the Investigational New Drug Application ("IND" for the testing of AEOL 10150 in healthy human volunteers in September 2014. The healthy volunteer safety studies are part of the Lung Acute Radiation Syndrome ("Lung-ARS" Medical Countermeasure ("MCM" program funded by BARDA under a five-year contract worth up to $118.4 million. BARDA is the division of the U.S. Department of Health and Human Services responsible for the advanced development of MCM for chemical, biological, radiological and nuclear threats.

Aeolus Pharmaceuticals to Present at OneMed Forum SF 2015 Conference
Marketwired - Tue Dec 30, 7:30AM CST
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the OneMed Forum SF 2015 Conference on Tuesday, January 13, 2015 at 10:50 AM PST (2:50 PM EST) at the Marriott Marquis in San Francisco.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 72

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 72

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 135

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 69

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
Sectra's RSNA AI Pitch Centers on Workflow, Not Hype

Updated Category News Views 95

Radiology has heard enough grand AI promises to fill a hospital basement, which makes Sectra's RSNA 2026 message refreshingly grounded. The Swedish imaging IT and cybersecurity company is putting its weight behind the unglamorous part of adoption: fitting AI into the daily diagnostic machinery without handing clinicians another awkward system to babysit. That is where...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 34

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal

Updated Category News Views 93

Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 46

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
AutoMobility LA Puts 2028 Mobility on Center Stage

Updated Category News Views 38

Los Angeles is cramming an awful lot of automotive ambition into one Thursday. AutoMobility LA opens November 19 at the Los Angeles Convention Center, one day before the LA Auto Show begins its November 20–29 public run. Yes, there will be coffee carts, awards, creators and the usual event confetti. But beneath that polished show-floor racket sits a fairly serious...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Bond Fund Faces Investigation for Misconduct

Updated Category News Views 327

Investigation of Easterly ROCMuni High Income Bond Fund Investors of the Easterly ROCMuni High Income Municipal Bond Fund are facing troubling times. Recently, the Portnoy Law Firm initiated an investigation regarding potential securities fraud associated with this investment vehicle. If you have lost money after investing in the Easterly ROCMuni High Income, it's...

Continue Reading
Japan's Economic Transformation: Unleashing Investment Potential

Updated Category News Views 271

Understanding the Shift in Japanese Equities Japanese equities are experiencing a resurgence, and this transformation is hard to ignore. The landscape of investment in Japan is shifting rapidly, and for those keeping an eye on the developments, there are compelling reasons to be optimistic. For years, conventional thought had deemed Japan as a country facing overwhelming...

Continue Reading
Pet Grooming Services Market Growth Driven by Humanization Trends

Updated Category News Views 129

Exploring the Pet Grooming Services Market Growth The pet grooming services market is witnessing a remarkable transformation, with anticipated growth projected to reach over USD 12.05 billion during the next decade. The rising phenomenon of pet ownership, coupled with the ongoing trend of humanization, is significantly influencing this expansion. The global market was...

Continue Reading
Investors Unite Against Dow Inc. in Class Action Suit

Updated Category News Views 181

Class Action Lawsuit Filed Against Dow Inc. Pomerantz LLP has announced the filing of a significant class action lawsuit against Dow Inc. (NYSE: DOW) and certain high-ranking officials within the company. This legal move signals a definitive call to action for investors who may have been adversely affected by the company’s alleged misrepresentations and omissions...

Continue Reading
Innovative Philanthropy: A New Challenge for MrBeast

Updated Category News Views 505

Revolutionizing Philanthropy: A New Challenge for MrBeast In an exciting initiative that aims to transform the landscape of modern philanthropy, the 144K Collective has reached out to the well-known YouTube personality and philanthropy leader Jimmy Donaldson, popularly known as MrBeast. This event, titled "144K Vs. The Beast," represents a novel approach to enhancing...

Continue Reading